NasdaqCM - Nasdaq Real Time Price USD

MEI Pharma, Inc. (MEIP)

3.2150 -0.0450 (-1.38%)
As of 2:16 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. David M. Urso B.A., Esq., J.D. CEO, President & Director 748.46k -- 1964
Dr. Richard G. Ghalie M.D., MBA Chief Medical Officer 627.76k -- 1958
Mr. Justin J. File CFO & Corporate Secretary -- -- 1970
Ms. Yomara Gomez-Naiden Senior Vice President of Operations & Quality -- -- --
Ms. Nicole Chyoko Iida Vice President of Legal Affairs -- -- --
Ms. Anne Frese Chief People Officer -- -- --
Dr. Robert D. Mass Strategic Advisor 201.68k -- 1954
Mr. David A. Walsey J.D., L.L.M. Senior Vice President of Corporate Affairs -- -- --

MEI Pharma, Inc.

11455 El Camino Real
Suite 250
San Diego, CA 92130
United States
858 369 7100 https://www.meipharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
46

Description

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Corporate Governance

MEI Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Feb 26, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Feb 21, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Feb 20, 2024
    S-3: Offering Registrations
    See Full Filing
  • Feb 13, 2024
    10-Q: Periodic Financial Reports
    See Full Filing
  • Jan 17, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

May 09, 2024 - May 13, 2024
MEI Pharma, Inc. Earnings Call

Related Tickers

REVB Revelation Biosciences, Inc.
2.1400
+2.39%
 
CWBR CohBar, Inc.
0.8000
0.00%
 
EVLO Evelo Biosciences, Inc.
0.0457
+3.39%
 
RPHM Reneo Pharmaceuticals, Inc.
1.6500
-1.79%
 
SNSE Sensei Biotherapeutics, Inc.
1.0047
+1.31%
 
RSPI RespireRx Pharmaceuticals Inc.
0.0009
+2.35%
 
GBIO Generation Bio Co.
3.0000
+0.33%
 
SPRO Spero Therapeutics, Inc.
1.4300
+0.70%
 
IPHA Innate Pharma S.A.
2.4000
-2.04%
 
AFMD Affimed N.V.
4.6950
-3.79%